Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TSOI Moreover, our journey has been one of perseverance and continuous improvement. From the early stages of 2014, when Tom and I began our pursuit, to conducting preclinical studies in 2018 using RU-486 combined with pterostilbene and other technologies integrated into our original StemVacs platform from 2015, we have come a long way. Now, in 2023, we stand on the cusp of a significant milestone as we prepare to introduce a new drug, FloraStilbene, derived from the fourth generation of StemVacs, for its first use in humans.
However, our ambitions extend even further. We firmly believe that RENO, our company, will be able to secure approval for this drug under 505(b)(2), enabling its availability beyond the existing Right To Try program. This means that FloraStilbene could potentially reach a broader range of individuals who could benefit from its therapeutic properties. It is not merely about the current access provided by Right To Try; it is about the potential for widespread availability.
Additionally, I would like to highlight that RENO is the company entrusted with taking our fourth generation StemVacs-V into clinical trials specifically designed for advanced breast cancer. This step signifies the progress we have made in our research and development efforts, as well as our commitment to addressing critical medical needs.
$TSOI Move aside, Wall Street wizards, because TSOI is here to show us how to make money moves! This stock is like the George Clooney of tickers, oozing richness and success. Just take a look at the chart—bullish weekly stochastics divergence and a price that soared above the 50-day MA. It's like the stock market's version of a Hollywood makeover montage, signaling the start of a bottoming process for TSOI. And let's not forget its past triumphs! TSOI is the classic underdog that ran all the way to a remarkable 17 cents in 2021. Now, it's not only TSOI but also a whole gang of OTC plays that are showing signs of life. It's like a resurrection of the stock market's greatest hits! So put on your dancing shoes, because TSOI and its comrades are ready to boogie their way to potential profits. It's time to dust off those trading strategies and get in on the action!
$TSOI It's like witnessing the resurrection of a legendary stock superhero! TSOI is back on the OTC scene, showcasing its rally potential and reminding us of its glory days. Just like a seasoned marathon runner, TSOI sprinted all the way to 17 cents in 2021, leaving investors breathless and craving for more. Now, with the stock rising again, it's like watching a sequel to an epic blockbuster. Will TSOI reach even greater heights this time?
$TSOI Today, it seems like the financial world had a case of 'market cap envy' as investors flocked to TSOI, the underdog of biotech companies. With a market cap of less than 8 million, TSOI is like the Cinderella of stocks, surrounded by its flashy, high-priced step-siblings trading at over 200 million. It's the classic tale of 'small-cap syndrome,' where the charming TSOI presents itself as a rare and precious gem in the OTC market, promising to be a 10X bagger.
$TSOI Furthermore...
Therapeutic Solutions International (TSOI) disclosed and patented data demonstrating that specific formulations of RU-486, the original abortion pill, have the potential to enhance the therapeutic effects of multiple immunotherapies. TSOI has developed the "FloraVax" platform, which consists of various formulations and combinations of RU-486 and cancer-targeting antigens. These formulations have shown the ability to enhance the effects of therapies that function, either wholly or partly, through immune modulation.
Dr. James Veltmeyer, Chief Medical Officer of TSOI and co-inventor of the patent, highlighted the biological similarities between cancer and pregnancy. Both cancer cells and fetal cells can escape immune attacks and invade tissues, including the mother's skin. They also exhibit rapid growth. Dr. Veltmeyer expressed surprise at the profound responses observed when combining the active ingredient of the abortion pill with the immune modulating approach developed by TSOI.
Timothy Dixon, President and CEO of Therapeutic Solutions International, the parent company of Res Nova, emphasized that both cancer and pregnancy utilize certain molecules such as VEGF to generate new blood vessels, IL-10 and HLA-G to suppress immune attacks, and matrix metalloproteases for tissue invasion. He pointed out that agents that disrupt maternal-fetal immune tolerance have previously shown anticancer activity, citing examples such as inhibitors of indoleamine 2,3-dioxygenase and various checkpoint inhibitors.
From a regulatory standpoint, RU-486 formulations fall under the 505(b)(2) pathway, which can expedite the time to commercialization. Famela Ramos, CEO of Res Nova Bio, expressed her interest in the repositioning of a compound with a controversial history towards a potential application that can gain widespread agreement.
$TSOI off to over 2 cents
Therapeutic Solutions International (TSOI) announced today paradigm shifting findings that further support the immunological connection between cancer and pregnancy. The company's research leverages the long-standing understanding that cancer can be viewed as an uncontrolled replication of pregnancy. Pregnancy has always been an immunological mystery due to the presence of foreign paternal proteins in the mother's body, which are tolerated to ensure the survival of the offspring.
Res Nova, the company's founders, have previously published research demonstrating that vaccination with placental tissues leads to immune-mediated tumor regression in animal models. They have also received FDA clearance for clinical trials based on these findings. This breakthrough supports the idea that cancer and pregnancy share common mechanisms, including the utilization of molecules like VEGF to generate new blood vessels, IL-10 and HLA-G to suppress immune attacks, and matrix metalloproteases for tissue invasion.
The implications of these findings are significant, potentially opening up new avenues for cancer treatment. The announcement highlights the potential use of an abortion pill to combat cancer, suggesting that understanding the immunological parallels between pregnancy and cancer may inform innovative therapeutic strategies.
Hey Charmaster...long time no see....i see PPS running to over 2 cents
$TSOI So, we have these esteemed Ass hats—oops, I mean Dr. Ricordi and Dr. Patel—rocking the boat with their Mesenchymal stem cell assays. The big question is, are they selling us a load of stem cell baloney or are they the real deal? I mean, we're not your run-of-the-mill dumb investors, right? We don't just believe any ol' story from Dr. Ricordi and his band of merry liars. No, no, we demand answers! Are those assays as impressive as they claim, or are we about to find ourselves knee-deep in stem cell shenanigans? Let's dig deep, my friends, and uncover the truth behind the scientific smoke and mirrors. Because when it comes to investing, we don't settle for anything less than the juiciest, fact-checked stem cell gossip! ------ just my opinion!
Let’s all support the groundbreaking, life-saving work produced by TSOI (Tissue Genesis) in collaboration with RTT and The Veltmeyer Institute for Biologics (VIAB)!! Their dedication to advancing biotechnology and regenerative medicine is truly commendable.
You can learn more about their incredible achievements and ongoing research by visiting their website: https://stkt.co/bQFsni6W
In addition, let's also recognize the excellent work being done by Res Nova Bio in their fight against Breast Cancer. Their contributions to cancer research and treatment are invaluable in bringing hope to countless individuals and families affected by this disease.
To find out more about Res Nova Bio and their efforts in combating Breast Cancer, please visit their website: https://stkt.co/_IvGN_S7
TSOI/VIAB and Res Nova Bio are both at the forefront of medical breakthroughs, offering hope and a brighter future for those in need. Let's join together in supporting their important work and spreading the message of hope and healing!
$TSOI So, if you ever have the privilege of meeting $TSOI CEO Dixon Lifestyles, be sure to bring your autograph book and maybe a pair of sunglasses, because when his signature lands on a contract, sparks fly, and the future looks bright – both figuratively and literally.
the rollercoaster ride of TSOI's share price after its agreement with Triton Funds! ?? It seems like things took a downward turn, and not even a modest half-million-dollar funding could prevent it. Brace yourselves for the twists and turns!
Now, let's take a closer look at Triton Funds and its partners. Maybe they hold the secret to their investment strategies. Who knows, they might have a list of stocks they're invested in. ?? It's like diving into a treasure trove of financial secrets! But where can we find this elusive information?
Is there a way to uncover Triton Funds' mysterious stock portfolio? ?? We find ourselves yearning for a Sherlock Holmes of the investment world, someone who can crack the code and reveal all the hidden gems. Can we solve this puzzling mystery?
In the quest for knowledge, we must be resourceful! Seek out the depths of the internet, traverse the databases, and consult the oracle of financial information. It's like embarking on a thrilling treasure hunt with emojis as our trusty companions! ?????????
Will we discover the secrets of Triton Funds' investments? Or will they remain shrouded in mystery, leaving us yearning for answers? The plot thickens! ????????
It's great to hear that $TSOI is fully prepared for potential Q&A sessions with the FDA regarding their research and development efforts. Being well-prepared and having a thorough understanding of their research can greatly enhance TSOI's ability to address any inquiries or concerns raised by the FDA.
If the FDA requests TSOI to perform immuno-assays, as mentioned in the provided forum post, TSOI's readiness to comply demonstrates their commitment to meeting the regulatory requirements and providing the necessary data for evaluation. The existence of a comprehensive drug master file (DMF) that contains all the available information about jadicells can be a valuable resource for TSOI in addressing FDA inquiries.
The DMF serves as a reference document that provides a compilation of the drug's chemistry, manufacturing, controls, preclinical data, and other relevant information. It plays a crucial role in demonstrating the safety, quality, and efficacy of a drug to regulatory authorities. If the FDA has specific questions that the DMF doesn't directly address, TSOI should be prepared to supplement the existing information and provide any additional data or analysis required to address those inquiries.
Consulting the DMF can be a starting point for the FDA in understanding TSOI's research and development efforts. However, it's important to note that the FDA may have specific questions or concerns that go beyond the information provided in the DMF. TSOI should be prepared to proactively address any potential knowledge gaps and provide the necessary clarifications or supplementary data to ensure a comprehensive evaluation by the FDA.
Overall, TSOI's proactive approach, preparation, and reliance on the DMF can help facilitate effective communication with the FDA and potentially expedite the regulatory review process. It's essential to maintain open dialogue and collaborate with regulatory authorities to address any questions or requirements they may have during the evaluation of TSOI's drug development.
Indeed, once the stock market recognizes the significance of ARDS (Acute Respiratory Distress Syndrome), it may realize the potential value of $TSOI's worldwide rights. If TSOI's drug successfully obtains a Biologics License Application (BLA) from the U.S. FDA, it can serve as a catalyst for expanding into other regions and target markets globally.
A BLA approval from the U.S. FDA is highly regarded internationally and often facilitates regulatory processes in other countries. Many regulatory agencies around the world consider FDA approvals as a valuable reference, which can expedite the approval process in their respective jurisdictions. Therefore, obtaining a BLA in the USA can act as a "golden ticket" for TSOI, providing a strong foundation for subsequent market entries into regions such as the EU, Asia, and Latin America.
Expanding into international markets can open up significant opportunities for TSOI, considering the global prevalence of respiratory conditions like ARDS, COPD, asthma, and others. By navigating regulatory pathways in different countries and obtaining necessary approvals, TSOI can access a larger patient population and potentially generate substantial revenues from its innovative biologics.
However, it's important to note that expanding into international markets involves additional complexities, including compliance with different regulatory requirements, market dynamics, reimbursement systems, and competition. TSOI will need to develop appropriate strategies, establish partnerships or distribution networks, and conduct clinical studies to meet the specific requirements of each region.
Ultimately, if TSOI successfully secures a BLA and strategically executes its global expansion plans, it can unlock significant growth potential and capitalize on the worldwide market demand for effective treatments for many respiratory diseases.
If TSOI is successful in pulling data from Phase 3 trials and successfully requests an upgrade of its indication from COPD (Chronic Obstructive Pulmonary Disease) to Phase 3, it could have significant implications for various other respiratory conditions such as asthma, bronchitis, emphysema, pulmonary fibrosis, and so on. This is because the drug master file and the accumulated data could potentially support the filing of these conditions as Phase 3 trials initially, streamlining the development process.
Expanding the indications for a drug beyond its initial target indication can be a promising strategy to maximize its potential impact and market opportunities. By leveraging existing data and the drug's mechanism of action, TSOI could potentially pursue additional indications in respiratory diseases, provided the drug's safety and efficacy are demonstrated through rigorous clinical trials.
Each additional indication may have its unique considerations and challenges, which would require careful planning, appropriate clinical studies, and engagement with regulatory authorities to ensure success.
Ultimately, TSOI's confidence in its drug's potential and its ability to successfully navigate the regulatory landscape will play a crucial role in determining the feasibility and success of pursuing multiple indications beyond COPD.
$TSOI is indeed a remarkable company with significant achievements in the field of treating lung and brain conditions. Their success in regenerative medicine and stem cell research, particularly in the area of RTT (Regenerative Therapies for Tissue) is commendable. It is understandable that those who are not aware of the company's accomplishments might harbor negative sentiments. Perhaps if they had taken the time to read the patents and understand the groundbreaking work done by $TSOI, they would have a different perspective.
It is worth noting that $TSOI holds over 20 JadiCell-related use patents, which demonstrate the depth of their intellectual property and innovative solutions. Additionally, their manufacturing patent in collaboration with Allogen Biologics showcases the potential for iPSC technology and StemVacs in the creation of various types of cells and tissues.
$TSOI is a well-managed and strategically positioned biopharmaceutical company, with a virtual holding structure that allows them to have control over their destiny. Their dedication to advancing regenerative medicine and improving patients' lives is evident in their accomplishments and ongoing research.
$TSOI, the superhero of the stock market, fighting off the evil unnamed third parties with their mighty keyboard strokes! It's like a Marvel movie, but with stock tickers instead of capes.
Forget about all those fake, manufactured vitriol dramas. $TSOI is the real deal, backed by a team of accomplished professionals who are probably too busy inventing new ways to save the world to bother with petty online battles.
And hey, they've got the validation to prove it! USPTO, sec.gov, FDA, FINRA, you name it! They've collected more stamps of approval than a passport in a world traveler's hands.
You know what's even cooler? $TSOI is like a fortress of financial awesomeness. No reverse splits ever! Your shares are like precious gems, protected by the impenetrable walls of expert management. Take that, market manipulators!
But why are these cowardly manipulators so threatened by $TSOI? Maybe it's because this biopharmaceutical powerhouse is growing so fast, it's attracting unwanted attention. It's like they're the pioneers of the Wild West, blazing a trail while dodging arrows from jealous rivals.
Remember, my friend, know what you own! Because in the world of stocks, you're your own best advocate. Flex those muscles, stand tall, and let the world know you're a proud $TSOI investor. ??
$TSOI is so undervalued, it's like finding a hidden gem in a haystack. You could blindly fall in love with it faster than a kid with a candy bar. Its market cap is under 5 million, which is basically pocket change for some people. I mean, who needs a yacht when you can own a biotech company for the price of a fancy latte? And let's not forget about those other biotechs with their tiny fractions of IP. It's like comparing a pebble to a mountain. TSOI's IP is so impressive, it could make even the most skeptical investors break into a happy dance. So, all you new investors out there, buckle up and get ready for a wild ride because TSOI is here to inject some serious comfort factor into your investment dreams.
$TSOI is causing quite the buzz in the trading world! Imagine, a biotech company trading at unbelievably low, low, low PPS levels around a mind-boggling 5 million market range. It's like finding a unicorn sipping tea with Bigfoot in your backyard. But hey, that's not even the best part! You can keep your health shining like a disco ball by buying their patented Quadramune and Nanostilbene nutraceuticals available on Amazon and Walmart. It's like getting a health boost while you shop for toilet paper and snack bars.
Now, hold on to your hats because this is where it gets wild. Brace yourselves, because the ongoing clinical phase 3 trials are about to spit out data that could make patients with COPD, Asthma, Bronchitis, and Emphysema jump for joy. We're talking about lung regeneration with JADICELLS. It's like giving your lungs a spa day, complete with cucumber slices and a heavenly massage. But that's not all! If you're someone who's been dancing on the edge of borderline suicide or battling those pesky depression tendencies, $TSOI might just be your knight in shining armor. Say goodbye to those blues and hello to a life full of shiny expectations, where you'll shine brighter than the sun itself and make even unicorns jealous!"
$TSOI, let's dive into the mystical realm of finance and witness the daring escapades of TSOI as it attempts to orchestrate a grand phase 3 clinical trial. But wait, what's this? A wild obstacle appears! It seems our brave hero is facing a challenge of epic proportions: insufficient funding and shares. Oh dear, how will they conquer this perilous mountain? Perhaps they'll tap into the hidden treasure chests of venture capitalists, convince them that TSOI is the next big thing, and sprinkle some fairy dust for good measure. Or maybe, just maybe, they'll make a magical wish upon a shooting star and find themselves showered with funds from the celestial heavens above. Ah, the mysteries of life! It's time to ponder and wonder, my dear friends. Who knows what fantastical possibilities await TSOI on this whimsical journey of clinical trials and financial prowess? Let's watch and see if they can pull off the ultimate pinky swear miracle!
$TSOI ??Oh, the magnificent FloraVax!??
If you haven't heard already, FloraVax is the revamped version of ValloVax, an angiogenesis-targeting immunotherapy that managed to win the prestigious FDA approval for clinical trials. But, wait for it, the plot thickens! The patent for ValloVax decided to take a well-deserved vacation, leaving the door wide open for a brand-new version to emerge.
Enter FloraVax, equipped with a special formulation that includes the FDA-cleared drug RU-486. This concoction has shown off its superior activity, outshining its predecessor, ValloVax. It's like witnessing an underdog rise to stardom and steal the show.
But wait, there's more! FloraVax isn't just sitting around, basking in its FDA approval and newfound glory. No, no! $TSOI (that's our beloved TSOI) has gone ahead and filed a patent on FloraVax, securing its rightful place in the world of medical advancements.
And the cherry on top? FloraVax has made its grand entrance under the Right to Try provision in the good ol' USA, allowing licensed physicians to wield its power. It's like a superhero ready to save the day!
So, my friends, let's take a moment to appreciate the foresight of $TSOI. They're not just a few steps ahead; they're miles ahead of the game. While the rest of the world may be napping, they're making groundbreaking moves and leaving everyone else in awe. Pay attention, folks, because greatness is happening right before our eyes. ??
$TSOI Ah, yes, the TSOI cult. Quite an interesting phenomenon, isn't it ? It's absolutely mind-boggling to witness these individuals who seem incapable of grasping reality. Clearly, seeking help at Veltmeyer Institute should be their top priority because, let's face it, nothing says "normal" like being ensnared in a cult.
$TSOI By combining the right doses of mifepristone with pterostilbene, our goal is to unleash the powers of cancer immunity. It's like a superhero team-up against cancer!
We've been hard at work with this drug since 2018, experimenting with various combinations. And guess what? Pterostilbene emerged as the winner, the ultimate sidekick to blend with RU-486 as a new adjuvant. It's like finding the perfect harmony in a scientific symphony.
Our upcoming clinical trial will focus on breast cancer, and we're eagerly awaiting its listing on CTDG (ClinicalTrials.gov). Keep an eye out for it, as the countdown to potential breakthroughs begins.
But wait, there's more! Introducing FloraVax, the upgraded version of ValloVax. ValloVax had its moment in the spotlight, approved by the FDA for clinical trials. However, its patent decided to take a nap. But fear not, we woke it up with a special formulation that includes the FDA-cleared drug RU-486. FloraVax has proven its superiority over ValloVax, like a champion emerging from the shadows.
And here's an important note: StemCells may not be the best choice in active cancer cases. We wouldn't want to inadvertently invite more trouble. However, they can play a role after cancer treatment, offering potential benefits. Let's be cautious and ensure we're not inadvertently giving cancer a VIP pass.
Science and medicine are full of surprises and possibilities. We're on a mission to explore them, pushing the boundaries and working towards better treatments for cancer patients. Together, we can make a difference!
$TSOI FloraStilbene is a patent-pending formulation of the drug mifepristone (RU-486) combined with pterostilbene. Mifepristone, commonly known as the abortion pill, has been investigated in combination with various substances since 2018. However, pterostilbene has emerged as the superior molecule to blend with RU-486 as a new adjuvant. The aim of this formulation is to stimulate cancer immunity. We are currently preparing for our first clinical trial, which will focus on breast cancer. The listing for this trial is expected to appear on CTDG (ClinicalTrials.gov) in the near future.
In addition, we have FloraVax, which is an angiogenesis-targeting immunotherapy originally known as ValloVax. ValloVax had received FDA approval for clinical trials but its patent has since lapsed. A new version of the immunotherapy was developed using a special formulation incorporating the FDA-cleared drug RU-486. FloraVax has demonstrated superior activity compared to ValloVax and can now be utilized under the Right to Try provision in the USA, allowing licensed physicians to administer it.
Ah, the hot garbage stock. The kind that's so hot, it might spontaneously combust at any moment. It's like investing in a flaming dumpster - exciting and unpredictable! . garbage talk on ihub and ST is the one that is responsible for the temperature of the stock. If it's garbage, well, that's their fault entirely.
$TSOI It is commendable that your primary concern lies with the well-being of patients rather than financial matters. The potential of a company like TSOI to treat individuals, especially those facing respiratory distress, is indeed a critical aspect that should be given utmost attention and differentiates with other biotech cos in the marketplace. Prioritizing the welfare of patients demonstrates a commitment to ethical principles and a genuine desire to see positive outcomes in healthcare.
Regarding your opinions about Tim, Thomas, and the management of TSOI, it seems that you have not altered your views. It is your prerogative to hold and express your opinions based on your own observations and experiences. However, it is important to remember that opinions can be subjective and vary from person to person.
While it's understandable that you may derive some satisfaction from certain events, it is essential to maintain a balanced perspective and ensure that the well-being of all stakeholders, including patients, remains at the forefront.
$TSOI The remarkable rise in TSOI's share price from subpenny to a staggering $0.17 within just 8 months in February 2021 is undoubtedly a testament to the sheer brilliance and unparalleled expertise of Tim and Tom. Clearly, their strategic brilliance and impeccable decision-making skills were already apparent during that period. How could anyone doubt their remarkable capabilities?
$TSOI nutraceuticals have introduced a groundbreaking innovation by developing an inhalation method that facilitates the crossing of the blood-brain barrier (BBB). This achievement marks a significant advancement in the field of nutraceutical research.
The blood-brain barrier is a highly selective and protective membrane that separates the bloodstream from the brain. Its primary function is to prevent harmful substances from entering the brain while allowing essential nutrients and molecules to pass through. Crossing this barrier has been a significant challenge in the medical and pharmaceutical industries.
In the past, few substances have successfully crossed the BBB, making it a complex and unexplored area of research. However, TSOI nutraceuticals has devoted substantial effort to understanding the intricate mechanisms of the BBB and has achieved a breakthrough in their approach.
It is important to note that the crossing of the BBB by nutraceuticals is an emerging field of study. TSOI nutraceuticals' work in this area signifies their commitment to rigorous scientific research and a focus on developing solutions that have the potential to heal and save lives.
As with any scientific advancement, it is essential for further research and clinical trials to be conducted to evaluate the efficacy and safety of this novel method. This ensures that the results are based on robust scientific evidence and can be confidently applied in clinical settings.
By studying and delving into the clinical results, we can better understand the implications and potential benefits of TSOI nutraceuticals' approach. Continued scientific exploration in this field holds the promise of advancing medical knowledge and providing new avenues for treatment that could have far-reaching impacts on patient care.
It is worth emphasizing the importance of relying on evidence-based science to validate and refine these developments. TSOI nutraceuticals' pioneering work opens up exciting possibilities for healing and saving lives, but it is through continued scientific inquiry that we can fully comprehend and harness the potential of this groundbreaking achievement.
$TSOI FloraStilbene is a compound developed by Therapeutic Solutions International, Inc. It is a derivative of resveratrol, a naturally occurring compound found in various plants. FloraStilbene is believed to have potential therapeutic benefits, particularly in the field of immunotherapy and cancer treatment.
"Wen EUA?" - EUA stands for Emergency Use Authorization, which is a regulatory pathway that allows the use of unapproved medical products during public health emergencies. It is up to the relevant regulatory authorities to decide when or if a product like FloraStilbene should receive EUA status. You may want to check the latest updates from Therapeutic Solutions International or regulatory agencies for any updates on the EUA status of FloraStilbene.
"Wen CTDG?" - one of these days the listing for this trial phase 3 will be on CTDG
"Wen Injected?" - If you're asking about the administration method of FloraStilbene, it would depend on the specific formulation and purpose. Different products may have different delivery methods, including oral administration, injection, or other routes. The appropriate administration method for FloraStilbene would be determined based on clinical trials, regulatory guidelines, and the intended use of the product.
$TSOI Aortic aneurysms can be a life-threatening condition if left untreated. They can grow and eventually burst, causing fatal internal bleeding. Traditional treatments for this condition involve surgical intervention, which can be invasive and risky. However, the use of stem cell-derived exosomes offers a promising new approach. Exosomes are small membrane-bound vesicles that are released by cells and contain various signaling molecules, including microRNAs and growth factors.
In the case of aortic aneurysms, stem cell-derived exosomes can be used to suppress the growth of aneurysms and potentially prevent them from rupturing. The results of a recent study demonstrate the effectiveness of this approach in an animal model, leading to the filing of a patent. This promising new treatment option could provide a less invasive and more effective way to treat aortic aneurysms, potentially saving countless lives in the process.
$TSOI's commitment to cutting-edge technology and expertise in stem cell research is not only impressive, but also important for advancing healthcare. Their efforts in developing innovative therapies could lead to breakthroughs in treating diseases and health conditions that were previously considered untreatable.
Moreover, TSOI's strong team of professionals is crucial for the success of the company. Their dedication and determination to drive the company forward is reassuring for investors, especially during challenging times.
As the stem cell industry is expected to grow substantially in the coming years, TSOI's position in the market is favorable. With more people recognizing the potential of stem cell therapy, the demand for TSOI's products and services is likely to increase, leading to a positive impact on the company's value.
Overall, investing in TSOI could be an opportunity to be part of a groundbreaking endeavor that could revolutionize healthcare. Despite the challenges, TSOI's long-term prospects look promising.
$TSOI I dont hesitate to ask the right question but that does not mean i am negative on $TSOI or about its CEO.
$TSOI It's a positive sign that the company is on the right track and that investors are taking notice. With the momentum building and the anticipation growing, it will be interesting to see how TSOI continues to progress and deliver on its promises in the months ahead.
$TSOI if you're in a company that hasn't done a reverse split, that's a win in my book! Keep believing in Tim Dixon, my friend. Who knows, maybe one day $TSOI shall be the next multi billion biotech Co
$TSO Clearly, CEO Tim Dixon is a genius who knows exactly what he's talking about, and anyone who disagrees must be the one misleading people.
$TSOI Company Forum, with all its riveting discussions about its science, clinical trials, product pipeline and dividends, could possibly be more fantastical than the old Penthouse forum, renowned for its high-quality journalism and factual reporting.
$TSOI is a promising retirement asset that I have invested in since 2019. In my opinion, it has the potential to pass FDA approval for use in all cancer treatments in the future. Given its potential, I believe that a big pharmaceutical company will acquire this company, or it will become one of the big pharma companies itself in the next 10 years. JADICELL has achieved remarkable success rates, exceeding 90% in treating other types of cancer, CTE, COVID-19, and lung treatment. It's only a matter of time before they develop treatments for other types of cancer, which is a high-demand market, making it a promising investment. Just my opinion and not a recommendation to buy or sell TSOI
$TSOI Wow, it sounds like the Veltmeyer Institute for Advanced Biologics is really making waves in the stem cell industry! With Phase III FDA approval for JadiCells, they're poised to be the first to market in the U.S., and with their focus on patient care, they're sure to make a positive impact on the lives of many. It's exciting to see the development of a domestic JadiCell manufacturing facility, and the potential for other physicians and clinics to license the product for patient treatments is a great opportunity for expansion. By recruiting and maintaining a network of medical practices, VI is making sure that their product is accessible to those who need it most. It's also impressive that they're aiming to be the number one company in the stem cell industry, providing patients with the peace of mind that comes with being treated in the U.S. Congratulations to the Veltmeyer Institute for their achievements so far, and best of luck with their future endeavors!
$TSOI Here is some additional information about the TSOI pipeline drugs CEO, Tim Dixon has listed on the forum:
ARDScells: This is a stem cell therapy being developed by Therapeutic Solutions International, Inc. for the treatment of Acute Respiratory Distress Syndrome (ARDS). It is currently in Phase 3 clinical trials.
JadiCell ARDS: This is another stem cell therapy being developed by TSOI for the treatment of ARDS. It is also in Phase 3 clinical trials.
JadiCell CTE: This is a stem cell therapy being developed by TSOI for the treatment of Chronic Traumatic Encephalopathy (CTE). It is currently in Phase 1/2 clinical trials.
JadiCell COPD: This is a stem cell therapy being developed by TSOI for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is also in Phase 1/2 clinical trials.
StemVacs-A: This is an immunotherapy being developed by Therapeutic Solutions International, Inc. for the treatment of COVID-19. It is currently in Phase 1 clinical trials.
StemVacs-V: This is another immunotherapy being developed by Therapeutic Solutions International, Inc. for the treatment of COVID-19. It is in Phase 1/2 clinical trials.
StemVacs-E, StemVacs-P, StemVacs-C, StemVacs-L, and StemVacs-H: These are all different versions of StemVacs, an immunotherapy being developed by Therapeutic Solutions International, Inc. for the treatment of cancer. They are all in preclinical stages.
JadiCell Epilepsy: This is a stem cell therapy being developed by TSOI for the treatment of epilepsy. It is in preclinical stages.
JadiCell_DC_Exosomes: This is a stem cell therapy being developed by TSOI that uses dendritic cell exosomes for the treatment of various diseases. It is in preclinical stages.
JadiCell Delta Variant and JadiCell IL-2: These are immunotherapies being developed by TSOI for the treatment of COVID-19. They are in preclinical stages.
JadiCell Leukine: This is a stem cell therapy being developed by TSOI for the treatment of various types of leukemia. It is in preclinical stages.
JadiCell Lithium: This is a stem cell therapy being developed by TSOI that uses lithium for the treatment of various diseases. It is in preclinical stages.
JadiCell Neurogenesis and JadiCell T-regs: These are stem cell therapies being developed by TSOI for the treatment of various diseases. They are in preclinical stages.
JadiCell ALS and JadiCell Schizophrenia: These are stem cell therapies being developed by TSOI for the treatment of ALS and schizophrenia, respectively. They are in preclinical stages.
TSOI-576: This is a small molecule drug being developed by Therapeutic Solutions International, Inc. for the treatment of various types of cancer. It is in preclinical stages.
Apoptocyte Cognition and Apoptocyte COPD: These are small molecule drugs being developed by Therapeutic Solutions International, Inc. for the treatment of cognitive dysfunction and COPD, respectively. They are in preclinical stages.
innaMune, LymphoBoost, and MemoryMune: These are all immunotherapies being developed by Therapeutic Solutions International, Inc. for the treatment of various diseases. They are in preclinical stages
"Another individual who lacks class and integrity has been identified as a deceitful gogbot. It appears evident that none of the approximately 9 gogbots on stocktwits, also known as 4.99.bots, are capable of reading and comprehending due to insufficient programming from the East.
Is there evidence to support the assertion that EUA and phase 3 were a confidence scam? If not, kindly refrain from making false accusations or keeping silent.
Recently, a scheme was executed using a patent we do not have access to. Who informed you of this? Was it Neil Riordan or Camillio Ricordi, the fraudulent international scammer Amit N. Patel, or someone else from arugula? TSOI are the owners of the 176' patent, and if Dr Patel licenses someone else to utilize cells intravenously, TSOI will take legal action against everyone, including their deceased mothers. Remember this, Neil Riordan." from CEO of TSOI , Timothy Dixon
$TSOI has had some recent positive developments. The rejection of the ReStem IPR challenge by the USPTO and the granting of a fourth QuadraMune® patent indicate that the company's intellectual property portfolio is being strengthened.
The initiation of a Phase III clinical trial for the treatment of Acute Respiratory Distress Syndrome (ARDS) is also a significant development. ARDS is a life-threatening condition that currently has a high mortality rate and can cause long-term complications in survivors. If TSOI's ARDScells treatment proves to be effective in the trial, it could potentially become the new standard of care for ARDS patients and improve their outcomes.
TSOI's drug master file and clinical data may give them a good foundation to build upon to possibly conduct phase 3 trials for treatment of ASTHMA, Bronchitis and Emphysema in immediate future targeting over 100 billion in annual sales for JADICELLS.